Real‐world evidence on clinical outcomes of people with type 1 diabetes using open‐source and commercial automated insulin dosing systems: A systematic review
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Aims: Several commercial and open‐source automated insulin dosing (AID) systems have recently been developed and are now used by an increasing number of people with diabetes (PwD). This systematic review explored the current status of real‐world evidence on the latest available AID systems in helping to understand their safety and effectiveness. Methods: A systematic review of real‐world studies on the effect of commercial and open‐source AID system use on clinical outcomes was conducted employing a devised protocol (PROSPERO ID 257354). Results: Of 441 initially identified studies, 21 published 2018–2021 were included: 12 for Medtronic 670G; one for Tandem Control‐IQ; one for Diabeloop DBLG1; two for AndroidAPS; one for OpenAPS; one for Loop; three comparing various types of AID systems. These studies found that several types of AID systems improve Time‐in‐Range and haemoglobin A 1c (HbA 1c) with minimal concerns around severe hypoglycaemia. These improvements were observed in open‐source and commercially developed AID systems alike. Conclusions: Commercially developed and open‐source AID systems represent effective and safe treatment options for PwD of several age groups and genders. Alongside evidence from randomized clinical trials, real‐world studies on AID systems and their effects on glycaemic outcomes are a helpful method for evaluating their safety and effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
McCambridge, J., Witton, J., & Elbourne, D. R. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.08.015 · Cited by 2,748
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., Kollman, C., Li, Z., Brown, A. S., & Close, K. L. (2019) · Diabetes Care · doi:10.2337/dc18-1444 · Cited by 793
6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744
DiMeglio, L. A., Acerini, C. L., Codner, E., Craig, M. E., Hofer, S. E., Pillay, K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12737 · Cited by 604
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Bekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250
One year clinical experience of the first commercial hybrid closed-loop system
Lal, R. A., Basina, M., Maahs, D. M., Hood, K., Buckingham, B., & Wilson, D. M. (2019) · Diabetes Care · doi:10.2337/dc19-0855 · Cited by 215
Real-world use of open source artificial Pancreas systems
Lewis, D., Leibrand, S., & Community, #. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816665635 · Cited by 180
Cited by
Open-source automated insulin delivery in type 1 diabetes
Burnside, M. J., Lewis, D. M., Crocket, H. R., Meier, R. A., Williman, J. A., Sanders, O. J., Jefferies, C. A., Faherty, A. M., Paul, R. G., Lever, C. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203913 · Cited by 183
A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems
Peacock, S., Frizelle, I., & Hussain, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01394-5 · Cited by 122
Self-citationForlenza, G. P., DeSalvo, D. J., Aleppo, G., Wilmot, E. G., Berget, C., Huyett, L. M., Hadjiyianni, I., Méndez, J. J., Conroy, L. R., Ly, T. T., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0578 · Cited by 99
The History, Evolution and Future of Continuous Glucose Monitoring (CGM)
Bender, C., Vestergaard, P., & Cichosz, S. L. (2025) · Diabetology · doi:10.3390/diabetology6030017 · Cited by 43
Petruzelkova, L., Neuman, V., Plachy, L., Kozak, M., Obermannova, B., Kolouskova, S., Pruhova, S., & Sumnik, Z. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0562 · Cited by 40
Metadata
- Authors
- Knoll, C., Peacock, S., Wäldchen, M., Cooper, D., Aulakh, S. K., Raile, K., Hussain, S., & Braune, K.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2021-11-24
- Volume
- 39
- Issue
- 5
- Pages
- e14741-e14741
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W3211872892
- Cited by
- 58
- References
- 16
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real‐world evidence on clinical outcomes of people with type 1 diabetes using open‐source and commercial automated insulin dosing systems: A systematic review. https://app.cochat.ai/papers/10.1111/dme.14741
- The paper
- Knoll, C., Peacock, S., Wäldchen, M., Cooper, D., Aulakh, S. K., Raile, K., Hussain, S., & Braune, K. (2022). Real‐world evidence on clinical outcomes of people with type 1 diabetes using open‐source and commercial automated insulin dosing systems: A systematic review. Diabetic Medicine. https://doi.org/10.1111/dme.14741
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.